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Side population (SP) refers to a group of cells, which is capable to eﬄux Hoechst 33342, a DNA-binding dye. SP cells exist both
in normal and tumor tissues. Although SP abundance has been used as an indicator for disease prognostic and drug screening
in many research projects, few studies have systematically examined the factors influencing SP analysis. In this study we aim to
develop a more thorough understanding of the multiple factors involved in SP analysis including Hoechst 33342 staining and
cell culture. RPMI-8226, a high SP percentage (SP%) human myeloma cell line was employed here. The results showed that SP%
was subject to staining conditions including: viable cell proportion, dye concentration, staining cell density, incubation duration,
staining volume, and mix interval. In addition, SP% was highest in day one after passage, while dropped steadily over time. This
study shows that both staining conditions and culture duration can significantly aﬀect SP%. In this case, any conclusions based on
SP% should be interpreted cautiously. The relation between culture duration and SP% suggests that the incidence of SP cells may
be related to cell proliferation and cell cycle phase. Maintaining these technical variables consistently is essential in SP research.
1. Introduction
Side population (SP) cells were first described as a subset of
adult mouse bonemarrowwith enriched hematopoietic stem
cells (HSCs) [1, 2]. This subset was characterized by its ability
to rapidly eﬄux the Hoechst 33342 DNA-binding dye and
therefore shows a Hoechst 33342lo profile on flow cytometry.
Specifically they display a distinct staining pattern, based
on the phenomenon of a diﬀerential emission of blue
(450 nm) versus red (670 nm) emission fluorescence upon
UV excitation, such that SP appears as a tiny population on
the lower left-hand side of a red (x)-blue (y) flow cytometry
scattergram. This diﬀerential blue-red emission allows clear
identification of a cell population that locates sideways
from the diagonal and was thus named “side” population.
Recent studies have shown the presence of SP cells in
many types of cancer including ovarian cancer, glioblastoma
cancer, lung cancer, nasopharyngeal cancer, gastrointestinal
cancers hepatocellular carcinoma, mesenchymal tumors, and
multiple myeloma [3–11]. SP cells in these types of cancer
showed significantly higher potential to initiate tumor in
NOD/SCID mice than their non-SP counterparts. They are
also more likely to be resistant to certain anticancer drugs
than non-SP cells. These results raised the significance of SP,
which would reveal a new insight for cancer research.
Although studies indicated that SP% varied among
diﬀerent types of cancer and from sample to sample as well
[3–11], some studies have used a quantitation of SP% as an
indicator for purposes such as prognostics and eﬃcacy of anti
cancer drugs [3, 8, 9, 11]. It is therefore important to under-
stand the factors that aﬀect SP%; otherwise, uncontrolled
experimental conditions would result in nonreproducible
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and inconsistent results. To date, some studies have indicated
that factors such as flow cytometry setting and gating
strategy, staining procedures, and cell viability issues aﬀect
the SP% significantly [1, 12–15]; however, few investigations
have approached this issue in a systemic way.
In this study, using the human myeloma cell line RPMI-
8226 as a convenient cellular model system in vitro, we
systematically explored the variables involved with optimiza-
tion and standardization of Hoechst 33342 staining variables
such as dye concentration, cell density, staining duration,
staining volume, and mix interval during staining as well
as cell viability prior to flow cytometry (FCM) analysis.
Importantly, we found that the time after cell subculture
is the single most important factor aﬀecting the SP% and
this has not been reported before. In summary, this study
suggests that both the Hoechst staining and subculture
duration aﬀect the proportion of SP. Hence, the conclusions
of any other studies based on the change of SP% should be
interpreted cautiously. Attempts to maintain these factors
in a more consistent manner is instrumental for building
reliable platforms for drug screening which target SP.
2. Materials and Methods
2.1. Cell Culture. The human myeloma cell line RPMI-8226
was obtained from the American Type Culture Collection
(Rockville, MD). RPMI-8226 cells were maintained in
RPMI-1640 (Invitrogen, Carlsbad, CA) containing 100 u/mL
of penicillin (Invitrogen), 100 μg/mL of streptomycin (Invit-
rogen), and 10% fetal bovine serum (FBS) (Sigma-Aldrich,
St Louis, MO). Cells were cultured in T75 or T25 flasks kept
in a humidified incubator with 5% CO2 at 37◦C. The cells
were seeded at the density of 0.2 × 106 cells/mL.
2.2. Cell Staining. RPMI-8226 cells were harvested after
culture for diﬀerent periods of time and then stained with
Hoechst 33342 dye (Invitrogen). Briefly, after discarding cul-
ture medium, cells were suspended in the staining medium
RPMI1640+ containing 2% FBS and 10mM HEPES buﬀer
(Invitrogen). Live cell number was counted at least twice
and adjusted to a final cell density of 1 × 106 cells/mL
by adding appropriate volume of warm staining medium.
Hoechst 33342 water solution (1mg/mL) was then added
to make a final concentration of 10 μg/mL followed by
incubation in a water bath at 37◦C for 90min with shaking
every 30min (except in the experiments that specifically
address the shaking factor). To help gate SP on flow
cytometry, samples treated with 1 μg/mL fumitremorgin C
(FTC) (Sigma, CITY), an ABCG2 transporter inhibitor, were
included during the entire staining procedure as controls.
Once incubation finished, samples were immediately put on
ice to stop dye eﬄux. Subsequently, the cells were centrifuged
for 5min at 300 g at 4◦C and resuspended in 100 μL of ice-
cold Hanks’ Balanced Saline Solution (HBSS) (Invitrogen)
containing 2% FBS, 100 u/mL of penicillin, 100 μg/mL of
streptomycin, and 10mM HEPES. The samples were kept
on ice before flow cytometry analysis. Propidium iodide
(PI) (Sigma) solution was added at a final concentration of
2 μg/mL to exclude dead cells just before flow analysis.
2.3. Exploration of Factors Aﬀecting SP%. To explore how cell
culture aﬀected SP%, RPMI-8226 cells were maintained in
culture medium for a range of time prior to being harvested
for downstream staining. Preparation of the samples in order
to examine the eﬀect of culture time course on SP% was as
follows: RPMI-8226 cells were seeded to four T-25 flasks at
0.2 × 106 cells/mL under the same conditions. The cells were
cultured for up to four days and then harvested at the end
of 1, 2, 3, and 4 days, respectively. Cells were counted using
trypan blue at least twice to adjust same staining density
(1 × 106 cells/mL) across diﬀerent experiment days. Two
batches of samples were prepared from diﬀerent but close
passages of cells. Cells were subsequently stained under the
conditions described as below. A subsequent independent
experiment was further performed at the laboratory of Hong
Kong Polytechnic University with diﬀerent batches of RPMI-
8226 passage and Hoechst dye.
We also investigated the SP% associated with an array
of diﬀerent staining conditions: Hoechst 33342 concen-
tration (ranging from 1–50 μg/mL), cell density (0.25 ×
106–2.00 × 106 cells/mL), volume (100–2000 μL), duration
(30–180min), shaking interval (10–90min), and viable cell
proportion (20–80%). Only one factor was varied and
examined each time, while the others were kept constant.
The standard protocol described before was employed for
the staining procedure except for the testing of the eﬀects
of cell viability prior to FCM analysis on SP%. For those
experiments, two tubes of cell suspensions with a density of
2 × 106 cells/mL were prepared in staining medium, one of
which was treated by incubation at 60◦C for 20min until all
the cells died. We then mixed 0.1, 0.2, 0.3, 0.4, 0.5mL treated
cells suspension with 0.5mL cell suspension without heat
treatment, respectively. The resulting samples with a range of
viable cell percentages were prepared for subsequent staining.
2.4. Flow Cytometric Analysis. Analysis was performed on a
four-laser BD LSR II flow cytometer (BD Biosciences, San
Jose, CA). The Hoechst 33342 dye was excited at 355 nm,
and its emission fluorescence was detected using 440/30 nm
(Hoechst 33342-Blue) and 670/40 (Hoechst 33342-Red) filter
systems. PI was excited at 488 nm, and its fluorescence was
detected using a 610/20 nm filter for dead cell exclusion.
The flow data was analyzed using FlowJo Version 8 software
(TreeStar, Ashland, CA, USA).
3. Results
This study is based on our previously published results
showing a convincing FCM pattern of stained RPMI-8226
cells with Hoechst 33342, where a remarkable SP of about
20% presented with a clear gap existing between SP and
non-SP cells [10]. Thus, we decided to harness the RPMI-
8226 myeloma cell line to explore the factors aﬀecting SP%.
The gating strategy used for the present study is shown in
Figure 1. The disappearance of SP cells observed in verapamil
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Figure 1: Flow cytometric analysis of RPMI-8226 stained with Hoechst 33342 and gating strategy for SP analysis. Sequential gating is shown
from (a) to (d). (a) Light scatter flow cytometry profile for cells based on forward scatter (FSC-A) related to size and refractive index, and
side scatter (SSC-A) related to granularity. (b) Singlet gating based on FSC-H versus FSC-A. (c) Dead cells excluded by PI binding. (d) SP
profile.
as well as FTC-treated samples was useful for the gating of SP
in flow scattergrams.
3.1. Eﬀect of Cell Culture Time Course. Previous studies
suggested that SP and non-SP cells were in diﬀerent cell cycle
phases [16]. We hypothesized that cell growth associated
with diﬀerent phases of the cell cycle would aﬀect SP and
non-SP distribution. To test for this hypothesis, we formally
examined how cell culture time would aﬀect SP%. The
RPMI-8226 cells continued to grow before reaching the
plateau stage on Day 4 after subculture as shown in Figures
2(a) and 2(b). Cells subcultured for diﬀerent days up to four
days were used to determine SP% using the standard staining
protocol. Surprisingly, we found that SP%was highest at Day
1, which was 5.1% and 2.3% for batch 1 and 2, respectively,
and then reduced to 2.0% and 0.1% for batch 1 and 2 at Day
4, respectively (Figures 2(c) and 2(d)).
3.2. Eﬀect of Hoechst 33342 Dye Concentration. We explored
how the dye concentration influenced SP%. Cells were
stained with a range of Hoechst 33342 concentration from
1 to 50 μg/mL and then assessed for (i) cytotoxicity as
measured by PI uptake indicating loss of plasma membrane
integrity and (ii) change of SP%. RPMI-8226 cell viability
was sensitive to Hoechst 33342 in a dose-dependent manner,
which indicated that this DNA-binding dye was toxic to
cells in higher concentrations (Figure 3(a)). The same gating
method was applicable for samples with dye concentration
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Figure 2: SP analysis of RPMI-8226 cells maintained in culture conditions for the indicated days. (a) Cell growth curve; (b) viable cell
proportion determined by PI staining by flow cytometry; (c) SP proportion over the culture day; (d) SP% change with time after subculture;
(e) SP flow cytometry profiles changed over the culture day. Data are mean ± SD value of triplicate samples in an independent experiment.
Bar indicates standard deviation. One of the three independent experiments is shown as representative data.
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Figure 3: Flow cytometric analysis of RPMI-8226 cells stained with Hoechst 33342. (a) The proportion of viable cells started to decrease
when dye concentration exceeded 15 μg/mL. (b) Flow cytometry profiles of SP analysis changed over dye concentration from 1 to 50 μg/mL.
(c) In another experiment with Hoechst 33342 concentration ranging from 7.5 μg/mL to 20 μg/mL, SP% dropped sharply from 26.3% at
7.5 μg/mL to 0.16% at 12.5 μg/mL. Data are mean ± SD value of triplicate samples in an independent experiment. Bar indicates standard
deviation. The experiment was repeated at least three times with similar results. One of the three independent experiments is shown as
representative data.
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Figure 4: Relation between SP% and viable cell proportion in
RPMI-8226. The experiment was repeated at least three times with
similar results. One of the three independent experiments is shown
as representative data.
<20 μg/mL (Figure 3(b)) as there was only small change
in flow cytometry profiles. However, we found that dye
concentration had a pronounced eﬀect on SP%. A sharp
drop of SP%was observed when dye concentration increased
from 7.5 μg/mL (26.3%) to 10 μg/mL (4.4%), which was
followed by a much gentle reduction to 12.5 μg/mL (0.16%)
and onwards (Figure 3(c)). This significant decrease in SP%
at 10 μg/mL or higher concentrations was not due to the
decrease in the percentage of live cells which were the same
at around 70% (Figure 3(a)). Thus, we suggested that the
optimum dye concentration for staining of RPMI-8226 cells
to be 10 μg/mL which was at the junction of the sharp and
the gentle slope of SP% (Figure 3(c)).
3.3. Eﬀect of Cell Viability. By using a fixed number of live
cells of the RPMI-8226, we continued to investigate the
issue of whether the presence of a diﬀerent number of dead
cells in the staining medium would aﬀect the staining of
SP cells leading to changes of SP% when gated on live cell
compartment. In this study, we manipulated the ratio of
live/dead cells by mixing diﬀerent numbers of heat-treated
dead cells to a standard number of live cells and then
measured the SP% of the live cells. The results shown in
Figure 4 indicate that SP% was inversely proportional to the
relative proportion of viable cell component. For instance,
the mean value of SP% was 3.5% for samples with 20%
live cells, in comparison to SP% of 1.1% when live cell
proportion increased to 70%.
3.4. Eﬀects of Staining Conditions. Next, we examined the
eﬀects of various components involved in the actual staining
procedure including staining cell density, volume of staining
solution, duration of staining incubation, interval between
mixing during incubation, and the staining temperature. The
results show that all of these factors contributed changes in
SP%.
While examining staining cell density, the viability of
stained cells was stable at around 70% for staining cell density
from 0.5× 106 to 2× 106 cells/mL (Figure 5(a)). No SP cells
were observed at the staining density of 0.75 × 106 cells/mL
or lower. The SP% increased sharply when the staining
cell concentration increased to 1.5 × 106 cells/mL or above
(Figure 5(b)).
Varying the duration of staining incubation showed that
there was a constant SP% when the incubation was at
least 90min. Reducing the incubation period resulted in an
increase of SP% while there was no change of viable cell
proportions. Finally, we investigated the eﬀects of the length
of shaking intervals during the incubation using 90min as
the standard incubation period. As shown in Figure 5(h), no
SPs were detected with frequent shaking of every 15min or
less, and then SP% proportionally increased in association
with increasing shaking interval time. The result showed
that a frequent mixing of the cells every 15 minutes may
dramatically result in negative staining results. It is therefore
important to follow a standard protocol of either a mixing
interval of every 30min or 45min.
In summary, in order to obtain a consistent SP%, it
is important to observe carefully all the above-mentioned
experiment requirements of viable cell proportion, dye
concentration, staining cell density, incubation duration,
staining volume, and mix interval, as well as the important
factor of the time after subcultured.
4. Discussion
It has been postulated that cancer stem cells (CSCs) resist
current drug therapies and repair DNA after radiation
treatment more eﬃciently than their diﬀerentiated, daughter
cells and that these CSCs are responsible for the recur-
rence of tumours after treatment [17–20]. Similarly we
have previously published that these CSCs survive standard
chemotherapeutics in multiple myeloma [10]. It is therefore
likely that the only way to cure cancer is to target against the
CSCs.
It has been reported that the number of companies
devoted to research into novel medicines targeting CSCs
doubled from 2007 to 2008 [21]. In addition, patents
covering developments in CSCs doubled to about 70 in 2007
[21]. Although there are only one or two drugs targeting
CSC molecules currently in Phase II or Phase III/IV clinical
trials, there are thirteen drugs in Phase I trials, with many
more in the development pipeline. All these point to the
fact that development of a robust drug screening platform
that focuses on testing of eﬀective compounds or medicines
targeting CSCs is urgently required and could have very
significant clinical impacts.
Few prospective systematic studies have examined the
factors influencing SP% in normal tissues or cancer cells.
In this study, using the human myeloma cell line RPMI-
8226 as a convenient cellular model system in vitro, we
systematically explored multiple factors, namely, Hoechst
33342 dye concentration, cell density, staining duration,
staining volume, mix interval during staining, and cell
viability prior to enumerating SP cells by FCM analysis.
We have highlighted the large variability in SP% which
is obtained when diﬀerent conditions are used and have
optimised the technical aspects of staining SP cells. With
Bone Marrow Research 7
0
20
40
60
80
100
0 0.5 1 1.5 2 2.5
Cell density (million/mL)
P
I-
n
eg
at
iv
e
ce
lls
pr
op
or
ti
on
(%
)
(a)
0
5
10
15
20
25
30
35
0 0.5 1 1.5 2 2.5
Cell density (million/mL)
SP
pr
op
or
ti
on
of
P
I-
n
eg
at
iv
e
ce
lls
(%
)
(b)
0
20
40
60
80
100
0 500 1000 1500 2000 2500
Staining volume (µL)
P
I-
n
eg
at
iv
e
ce
lls
pr
op
or
ti
on
(%
)
(c)
0 500 1000 1500 2000 2500
Staining volume (µL)
0
1
2
3
4
5
SP
pr
op
or
ti
on
of
P
I-
n
eg
at
iv
e
ce
lls
(%
)
(d)
0
20
40
60
80
100
0 30 60 90 120 150 180
Staining duration (min)
P
I-
n
eg
at
iv
e
ce
lls
pr
op
or
ti
on
(%
)
(e)
0 30 60 90 120 150 180
Staining duration (min)
0
1
2
3
4
SP
pr
op
or
ti
on
of
P
I-
n
eg
at
iv
e
ce
lls
(%
)
(f)
0
20
40
60
80
100
0 30 60 90 120
Shaking interval (min)
P
I-
n
eg
at
iv
e
ce
lls
pr
op
or
ti
on
(%
)
(g)
0 30 60 90 120
Shaking interval (min)
0
5
10
15
SP
pr
op
or
ti
on
of
P
I-
n
eg
at
iv
e
ce
lls
(%
)
(h)
Figure 5: Eﬀect of staining conditions on viable cell and SP%. (a) Live cell proportion remained relatively stable when staining cell density
increased. Cell density ranged from 0.25 × 106 to 2.00 × 106 cells/mL. (b) SP percentage increased with increasing cell density. (c) Live
cell proportion remained stable when staining volume increased from 100 to 2000 μL. (d) SP percentage decreased with increasing staining
volume. (e) The viable cell proportion prior to flow cytometry analysis was stable when increasing staining duration from 30min to 150min.
(f) SP percentage decreased with increasing staining duration and plateaued after 90min. (g) The viable cell proportion prior to flow
cytometry analysis was stable when mixing interval time changed from 15 to 90min. (h) SP percentage increased with the decrease of mixing
interval. Data are mean ± SD value of triplicate samples in an independent experiment. Bar indicates standard deviation. The experiment
was repeated at least three times with similar results. One of the three independent experiments is shown as representative data.
8 Bone Marrow Research
regards to cell viability, a previous study has also shown that,
for consistent SP staining, the cell count before the Hoechst
staining should include all cells ranging from dying, dead, to
live cells [14]. The same group also suggested that Hoechst
concentration and toxicity curves should be independently
determined for each new tissue or cell type being tested [14].
Importantly, we found that the time after cell subculture
is an important factor aﬀecting the SP% which has not been
reported previously. While this factor will not aﬀect the
staining of SP in primary tissues, we envisage that a drug
screening platform targeting SP for various cancer types will
utilize stable cell lines. Thus, this new finding should lead to
the modification of the preparation of cell samples for drug
screening purposes. Furthermore, since RPMI-8226 harbors
a rich and constant source of SP cells, it could be used as
the positive control for this platform and for the detailed
monitoring of the day-to-day variation of Hoechst staining
performance.
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